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Monoclonalantibodies have been the most successful therapeutics ever brought to cancer treatment by immunetechnologies. The
use of monoclonal antibodies in B-cell Non-Hodgkin’s lymphomas (NHL) represents the greatest example of these advances, as
the introduction of the anti-CD20 antibody rituximab has had a dramatic impact on how we treat this group of diseases today.
Despite this success, several questions about how to optimize the use of monoclonal antibodies in NHL remain open. The best
administration schedules, as well as the optimal duration of rituximab treatment, have yet to be determined. A deeper knowledge
of the mechanisms underlying resistance to rituximab is also necessary in order to improve the activity of this and of similar
therapeutics. Finally, new antibodies and biological agents are entering the scene and their advantages over rituximab will have to
beassessed.Wewilldiscusstheseissuesandpresentanoverviewofthemostsigniﬁcantclinicalstudieswithmonoclonalantibodies
for NHL treatment carried out to date.
1.Introduction
In 1975, Kohler and Milstein heralded a new era in antibody
research with their discovery of hybridoma technology
[1]. Mouse hybridomas were the ﬁrst reliable source of
monoclonal antibodies. Subsequently, the introduction of
recombinant technologies, transgenic animals, and phage
display technology has modernized selection, humanization
and production of therapeutic antibodies. The use of mAbs
in cancer treatment stems from the idea that these, because
oftheirintrinsic speciﬁcity,couldbeused toselectively target
cancer cells based on the expression of one or more antigens.
In such approaches, antibodies could be used alone or be
conjugated to toxins, radioactive moieties, or enzymes in
order to achieve toxic concentrations of these agents in the
cancerous tissues while sparing healthy organs.
Indeed, since their initial discovery, more than 20mAbs
have been approved by the US Food and Drug Admin-
istration (FDA) for the treatment of several conditions,
including several types of cancers. This success has opened
new therapeutic perspectives and prompted research eﬀorts
aimed to improve their activity, select for those patients who
will most beneﬁtfromthem,and,potentially,toexpand their
therapeutic indications. The anti-CD20 mAb rituximab is
one of the best examples of this new class of therapeutics,
since it has rapidly become a key part of the pharmacological
schemes used to treat Non-Hodgkin’s lymphomas (NHLs).
Moreover, due to its capacity to eliminate B lymphocytes, it
hasrecentlybeenappliedinimmune-mediateddisorders[2].
Here, we will focus on the use of rituximab in the
treatment of NHL, on the clinical issues associated with this
therapeutic, and on the most recent advances in the ﬁeld of
lymphoma immunotherapy.
2.TumorAntigensinNHL
When designing a therapeutic approach for NHL, cancer
immunologists face the issue of selecting the best target
antigen. Tumor antigens are traditionally divided in tumor-
speciﬁc antigens (proteins that are uniquely expressed by
cancer cells) and tumor-associated antigens (molecules that
are expressed by cancer cells, although their expression is
also found on normal cells) [3]. Ideally, an immune response2 Clinical and Developmental Immunology
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Figure 1: Schematic representation of the putative mechanisms mediating rituximab’s anticancer activity in NHL cells. The anti-CD20
monoclonal antibody rituximab has several mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC), which
involves recruitment of eﬀector cells, mediated by Fcγ receptors; complement-dependent cytotoxicity (CDC); apoptosis induction.
against tumor antigens should destroy tumor cells without
damaging normal cells. Thus, cancer-speciﬁc antigens would
be the ﬁrst choice. Unfortunately, true cancer-speciﬁc anti-
gens, such as new proteins resulting from fusion oncogenes,
are not frequent in NHL. Another important issue is to
ensure that the chosen antigen does not mutate in a way
that allows cancer cells to avoid destruction by the immune
system [3].
The cell surface protein CD20 is a 33-kDa protein
expressed by mature B cells and most malignant B cells, but
not by pre-B cells or diﬀerentiated plasma cells [4–8]. In
vitro studies have revealed that CD20 acts as a calcium ion
channel [9, 10], and may also activate intracellular signaling
through itsabilityto associate with theB-cell receptor(BCR)
[11]. Interestingly, CD20’s ability to induce cytosolic Ca2+
ﬂux appears to be BCR dependent. Rituximab (Rituxan,
Mabthera), is the ﬁrst anti-CD20 monoclonal antibody
approved by the Food and Drug Administration (FDA)
(on November 26, 1994) for the treatment of relapsed or
refractory, CD20+ follicular lymphoma (FL). It is a chimeric
anti-CD20 antibody derived from the mouse mAb 2B8,
targeting CD20 antigens, following replacement of the heavy
and light chain constant regions with the corresponding
regions of a human IgG1 mAb. Importantly, rituximab
depletes both malignant and normal CD20+ Bl y m p h o c y t e s
[4, 12, 13].
3.Rituximab’sModeof Actionin
Lymphoma Cells
Although the exact in vivo mechanisms of action for
rituximab arenotfully understood,themechanisms ofB-cell
killing by this mAb have been exhaustively analyzed [14].
Brieﬂy, the major mechanism of rituximab-induced B-
cell depletion involves antibody-dependent cell-mediated
cytotoxicity (ADCC) and complement dependent cytotox-
icity (CDC) [15]. Additionally rituximab was reported to
directly induce apoptosis, inhibit B-cell proliferation, and to
enhance the cytotoxic activity of chemotherapeutic agents
[16]( Figure 1).
Rituximab-induced CDC is triggered upon rituximab
binding to B cells with consequent initiation of the comple-
ment cascade starting from C1 activation. This mechanism
causes osmotic lysis of neoplastic B cells [13, 14]. ADCC is
triggered by the interaction between rituximab and the Fc
receptor of natural killer (NK) cells [13, 14]. Once activated,
NK cells release small proteins, including perforin and
granzymes, which in turn form pores in the malignant B-cell
membrane, and thus induce apoptosis or osmotic cell lysis.
Finally, recent data demonstrate the novel role of rituximab
as a signal-inducing antibody, and as a chemosensitizing
agent, capable of negative regulation of major survival
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Besides these mechanisms, rituximab’s activity appears
to be linked, at least in part, to its signaling via CD20.
In this ﬁeld, studies in B-NHL cell lines revealed sev-
eral mechanisms involved in rituximab-mediated chemo/
immunosensitization. Rituximab was shown to inhibit the
p38 mitogen-activated protein kinase, nuclear factor-κB
(NF-κB),extracellularsignal-regulated kinase 1/2 (ERK1/2),
and Akt antiapoptotic survival pathways [17]. All of these
eﬀects result in upregulation of PTEN and of Raf kinase
inhibitor protein (RKIP) [18], in the downregulation of
antiapoptotic gene products, such as Bcl-2, Bcl-xL and Mcl-
1, and, as a result, in chemo/immunosensitization [19].
In addition, treatment with rituximab inhibits the overex-
pressed transcription repressor Yin Yang 1 (YY1) [20]. YY1
downregulates Fas and DR5 expression and its inhibition
leadstosensitizationtoFasligand andtumornecrosisfactor-
related apoptosis-inducing ligand- (TRAIL-) induced cell
death [21].
Interestingly, recent studies also show that rituximab
strongly aﬀects BCR signaling [22]. Pretreatment of lym-
phoma cells or healthy B-cells with rituximab results in
a time-dependent inhibition of the BCR-signaling cascade
involving Lyn, Syk, PLCγ2, Akt, ERK, and calcium ﬂux. Such
inhibitory eﬀects by rituximab are associated with a decrease
in raft-associated cholesterol, inhibition of BCR relocaliza-
tion to lipid rafts, and BCR downregulation. Since BCR
signaling appears to be crucial for healthy and malignant B
cell survival and expansion [23–25], this mode of action of
rituximabcouldactuallyhaveanimportantroleinmediating
its anticancer activity.
The relative importance of each mechanism of action of
rituximab is likely to vary with the type of tumor and the
type of treatments that are administered together with this
mAb. CDC and ADCC appear to be important to target
leukemia/lymphoma cells circulating in the bloodstream
[26]. Conversely, an immunological mechanism of action
s e e m st ob el e s si m p o r t a n ti nt h ep r e s e n c eo fn o d a la n d
extranodal involvement.
4.Rituximab’sApplicationsin
HematologicalMalignancies
We will discuss here the current therapeutic applications of
rituximabin indolentNHL,diﬀuselargeBcell non-Hodgkin
lymphoma (DLBCL), and in B-cell chronic lymphocytic
leukemia (B-CLL). Although trials may have had endpoint
deﬁnitions that are not always identical, almost all deﬁned
completeresponse (CR)asthecompletedisappearanceofthe
symptoms and signs of lymphoma (including bone marrow
clearing for >28 days), and partial response (PR) as a >50%
decrease in the size or number of the lymphomas lesions,
without any evidence of progressive disease for >28 days. CR
and PR together represent the objective response (OR) rate
[4, 27].
4.1. Follicular and Low Grade Lymphoma. Until the early
90’s, the ﬁrst-line therapy in symptomatic low-grade NHL
was chlorambuciland prednisone [42].Subsequently,several
randomized trials showed the eﬃcacy of rituximab in com-
bination with other chemotherapeutic agents such as ﬂu-
darabine (R-F), ﬂudarabine, and cyclophosphamide (R-FC),
ﬂudarabine,cyclophosphamideandmitoxantrone (FCM-R),
cyclophosphamide, vincristine, and prednisone (R-CVP),
CVP plus mitoxantrone (R-CNOP), ﬂudarabine, dexam-
ethasone, and mitoxantrone (R-FND) as well as CHOP (R-
CHOP) [28, 43–45]( Table 1). The clinical response rates of
rituximab-containing regimens were encouraging, with an
OR rates consistently around 95% and with a CR and PR
rates ranging from 45% to 100%, and from 0% to 52%,
respectively.
Importantly, clinical data on the beneﬁt of rituximab
combined with chemotherapy has also become available in
patients with relapsed or refractory indolent B-cell NHL.
Also here, the results are very encouraging, with OR of 81%
for R-CVP, 97% for R-FC, 88% for R-CHOP, and 95% for
FCM-R respectively [4, 46].
Finally,theeﬃcacyofrituximabmonotherapyinpatients
with relapsed or refractory CD20-positive low-grade or
follicular lymphoma was examined in noncomparative mul-
ticentretrials[33–35,47–55].The overallresponse rateswere
38%–48% after a 4-week therapy with rituximab, and 57%
after 8 weeks of rituximab administration. CR rates ranging
between 3 and 17% were recorded in these studies.
Remarkably, studies show that, in FL, sequential admin-
istration of standard chemotherapy followed by rituximab
induces molecular clearance (as detected by PCR for the
Bcl-2/IgH rearrangement) in more than 70% of the patients
[42, 43, 56]. The actual clinical impact of achieving a
molecular response in FL still has to be determined,
since long-term remissions have been reported also in
patients with persistently detectable Bcl-2/IgH rearrange-
ment [57]. Moreover this rearrangement may occasion-
ally be found in healthy peripheral blood lymphocytes
[58]. In fact, a recent study by van Oers and coworkers
suggests that BCL-2/IgH polymerase chain reaction status
at the end of induction treatment would not be predic-
tive for progression-free survival in relapsed/resistant FL
[59]. Nonetheless, the above-mentioned studies support
the eﬃcacy of rituximab in FL, and indicate its poten-
tial for treating minimal residual disease in this type of
disorder.
In summary, the current guidelines for the treatment
of FL recommend that rituximab is administered in
combination with standard chemotherapy in previously
untreated stage III–IV FL, and at ﬁrst relapse (at a dosage of
375mg/m2 on day 1 of each chemotherapy cycle, for up to
eight doses). Rituximab is recommended as a monotherapy
for stage III–IV chemoresistant FL, or at second (or
subsequent) relapse after chemotherapy (375mg/m2 once
weekly for four doses) (http://www.ema.europa.eu/docs/en
GB/document library/Summary of opinion/human/000165/
WC500097025.pdf).
4.2. DLBCL. After the disappointing results obtained with
third-generation chemotherapy regimens in the United
States, the CHOP regimen was reverted to as the standard of4 Clinical and Developmental Immunology
Table 1: Principal clinical trials of chemotherapy plus Rituximab versus chemotherapy alone in NHL.
Lymphoma Subtype Treatment Patients
(no.)
%O v e r a l l
response rate
(P value)∗
Median Follow-up
(mo.) Reference
Follicular CVP versus
R-CVP 321 57 versus
81 (<.001) 53 Marcus et al. [28]
Follicular CHOP versus
R-CHOP 428 90 versus
96 (=.011) 18 Hiddemann et al. [29]
Follicular CHOP versus
R-CHOP 465 72.3 versus
85.1 (<.001) 39,4 van Oers et al. [30]
Follicular FCM versus
R-FCM 176 71 versus
95 (=.01) 26 Forstpointner et al. [31]
Follicular MCP versus
R-MCP 201 75 versus
92 (=.009) 47 Herold et al. [32]
relapsed/refractary
low grade R 37 46 13,4 Maloney et al. [33]
relapsed/refractary
low grade R 30 47 19 Feuring-Buske et al. [34]
relapsed/refractary
low grade R 166 48 19,5 McLaughlin et al. [35]
DLBCL CHOP versus
R-CHOP 399 63 versus
76 (=.005)∗ 24 Coiﬃer et al. [36]
DLBCL CHOP versus
R-CHOP 824 84 versus
93 (=.0001)∗∗ 34 Pfreundschuh et al. [37]
DLBCL CHOP versus
R-CHOP 632 57 versus
67 (=.05)∗∗ 42 Habermann et al. [38]
DLBCL CHOP versus
R-CHOP 122 75 versus
94 (=.0054) 18 Lenz et al. [39]
B-CLL FC versus R-FC 552 58 versus
69.9 (=.0034) 25 Robak et al. [40]
B-CLL FC versus R-FC 817 82.5 versus
87.2 (=.012)∗∗ 37,7 CLL8- German CLL
Study Group∗∗∗ [41]
∗CR, CR-unconﬁrmed, partial response.
∗∗CR rate.
∗∗∗3-year OS.
therapy. The eﬀorts to introduce rituximab in the treatment
of this aggressive hematological disease led to two essential
clinical trials: the Mabthera International trial (MinT) [37]
and the Groupe d’Etude des lymphomes de l’Adulte study
(GELA) [36]. The ﬁrst one involved young, the latter elderly,
DLBCL patients. In the multicenter study conducted by
Coiﬃer and colleagues, therapy using rituximab combined
with standard CHOP chemotherapy demonstrated a higher
eﬃcacy than CHOP alone, in terms of both event-free
survival at 2 years (57% versus 38%, P<. 001), overall
survival at 2 years (70% versus 57%, P<. 01), and CR
rate (76% versus 63%, P<. 01). Likewise, the MinT
study showed an increased OS of the combined rituximab-
adding regimen, compared to standard therapy, from 84%
to 93%. These results led to FDA approval of rituximab
in combination with CHOP chemotherapy for previously
untreated patients with DLBCL. Whether or not all patients
need rituximab has been questioned. Studies from France
and the American National Cancer Institute suggested that
the beneﬁt of rituximab would be observed in patients with
tumors overexpressing Bcl-2. On the other hand, a recent
report from the French group shows beneﬁt in both Bcl-2-
positive and Bcl-2-negative lymphomas using the method
of competing risks [27, 60, 61]. Therefore, the question of
w h e t h e rm o l e c u l a rf e a t u r e ss h o u l do rw i l ld i r e c tt r e a t m e n t
decisions remains unanswered.
Finally, for recurrent DLBCL, the standard of care is
salvage chemotherapy followed by high-dose chemotherapy
with stem cell transplantation. Also in this setting, rituximab
proved to be eﬀective and has been incorporated into salvage
chemotherapy regimens, since it may improve the overall
response rate with ICE (ifosfamide, carboplatin, and etopo-
side) and DHAP(dexamethasone, high-dose cytarabine,and
cisplatin) [62].
In summary rituximab is approved for previously
untreated DLBCL patients in combination with CHOP
chemotherapy and with salvage chemotherapy regimens in
relapsed/refractory patients. The recommended rituximab
dosage is 375mg/m2 on day 1 of each chemotherapy cycle,
for up to eight doses (http://www.ema.europa.eu/docs/en
GB/document library/Summary of opinion/human/000165/
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4.3. Rituximab and Autologous Stem Cells Transplantation
for Advanced Stage DLBCL. Young high-risk patients with
DLBCL achieving a complete remission after a complete
course ofchemotherapy are likelyto beneﬁt from autologous
stem cell transplantation (ASCT)[27,63]. Severalstudiesare
assessing the role of rituximab as part of high-dose regimens
(HDT) pre-ASCT in DLBCL because of its eﬀectiveness,
limited toxicity, and its ability to deplete B cells. In this ﬁeld,
in a 2-year study by Khouri and colleagues evaluating the
eﬃcacy and safety of high-dose rituximab in combination
with high-dose BEAM and ASCT, the OS was 80% for the
study group compared to 53% for the control group [64].
Superior survival rates have also been reported for patients
who become PCR negative for BCL2/JH rearrangements in
peripheral blood or bone marrow compared with those who
remain positive.
4.4. Rituximab Maintenance Therapy for FL and DLBCL.
Despite the fact that rituximab used in combination with
chemotherapy has been shown to prolong the survival of
patients with NHL, residual lymphoma cells (which then
become responsible for disease relapses) frequently remain
[65]. As a matter of fact, NHL relapses continue to be
an important clinical issue. Therefore, several randomized
trials have been conducted in order to analyze the beneﬁt
of rituximab maintenance treatment in NHL [66–68]. The
studies that were done for FL adopted diﬀerent schemes for
induction (rituximab 375mg/m2 weekly × 4 in Ghielmini et
al. and in Hainsworth et al.; CHOP or R-CHOP in van Oers
et al.; ﬂudarabine, cyclophosphamide, and mitoxantrone
with or without rituximab in Forstpointner et al.) as well
as for the maintenance treatment (375mg/m2 intravenously
weekly for 4 weeks at six-month intervals in Hainsworth
et al.; 375mg/m2 intravenously weekly for 4 weeks for
Ghielmini et al.; 375mg/m2 rituximab intravenously once
every 3 months in van Oers et al.; 2 further courses of
4-times-weekly doses of rituximab after 3 and 9 months
in Forstpointner et al.). However, overall, they unequivo-
cally show that rituximab maintenance increases event-free
survival (EFS) and duration of response in indolent NHL.
In Ghielmini et al., at a median followup of 35 months,
the median EFS was 12 months in the no-maintenance
group versus 23 months in the prolonged treatment arm
(P = .02) [69]. The authors reported that the diﬀerence
was particularly notable in chemotherapy-naive patients (19
versus 36 months; P = .009) and in patients responding to
induction treatment (16 versus 36 months; P = .004). In the
study by van Oers et al., rituximab maintenance signiﬁcantly
improvedEFScomparedwithobservation(median,3.7years
versus 1.3 years; P<. 00), both after CHOP induction
(P<. 001) and R-CHOP (P = .003) [30]. The 5-year
overall survival (OS) was 74% in the rituximab maintenance
arm, and it was 64% in the observation arm (P = .07).
Finally, also in the trial by Forstpointner and colleagues,
response duration was signiﬁcantly prolonged by rituximab
maintenance, with the median not being reached in this
evaluation versus an estimated median of 16 months in the
observation group (P = .001) [31]. This beneﬁcial eﬀect was
also observed when analyzing FL (P = .035) and mantle cell
lymphoma (P = .049) separately.
Unlike in indolent NHL, rituximab maintenance therapy
in DLBCL has failed to demonstrate beneﬁt in the published
clinical trials [38].
In conclusion, the current guidelines recommend the
use of rituximab as a maintenance therapy only in relapsed
or refractory follicular lymphoma responding to induction
therapy with chemotherapy with or without rituximab.
The recommended dosage of rituximab is 375mg/m2
once every 3 months until disease progression or for a
maximum of 2 years (http://www.ema.europa.eu/docs/en
GB/document library/Summary of opinion/human/000165/
WC500097025.pdf).
4.5. B-cell Chronic Lymphocytic Leukemia (B-CLL). B-CLL
is a heterogeneous disorder with a variable course (i.e.,
followingdiagnosis,survivalrangesfrommonthstodecades)
and risk factors such as age and performance status should
beconsideredwhenselectingthemostappropriatetreatment
option [70].
Rituximab monotherapy is generally not associated with
sustained responses in B-CLL, possibly reﬂecting altered
rituximab pharmacokinetics in patients with B-CLL [40, 70–
73]. However, studies show that the addition of rituximab
to ﬂudarabine plus cyclophosphamide (FC) does improve
clinical outcomes in B-CLL patients. The ﬁrst study, known
as CLL8, was conducted by the German CLL Study Group
on 817 previously untreated B-CLL patients (ClinicalTri-
als.gov number, NCT00281918). The second trial, known as
REACH, enrolled 552 patients with relapsed or refractory
B-CLL following prior systemic therapy [40]. Both studies
showed a beneﬁt in terms of OS rates in the R-FC arm
versus FC arm (86% versus 73 % in the CLL8 trial and 54%
versus45%intheREACH).Inaddition,thebeneﬁtofadding
rituximab to chemotherapy in B-CLL was shown by several
other trials [40, 74–77].
Interestingly, since rituximab plus FC represents the
standard treatment for B-CLL, clinical studies compared the
conventional regimen to rituximab plus low-dose FC (i.e.,
FCR-Lite) or to sequential FC and rituximab [49], since
these alternative regimens are expected to be associated with
less grade 3 or 4 neutropenia than the conventional R-FC
regimen [5, 50].
The current international guidelines recommend that
chemoimmunotherapy regimens with R-FC are preferred
as the ﬁrst-line treatment for advanced CLL (stage II–IV)
in patients without del(17p) who are aged <70 years or
aged >70 years without signiﬁcant comorbidities. Among
patientswith relapsed orrefractory disease, those with along
response (i.e., >3 years) can be retreated with one of the
ﬁrst-line treatment options. Various chemoimmunotherapy
options are suggested for patients with a short response
(i.e., <2 years) (e.g., rituximab may be administered in
combination with FC or with CHOP). The recommended
dosage of rituximab is 375mg/m2 the day before starting
chemotherapy, followed by 500mg/m2 on day 1 of cycles
2–6 (National Comprehensive Cancer Network. NCCN6 Clinical and Developmental Immunology
clinical practice guidelines in oncology: non-Hodgkin’s lym-
phoma).
5.Tolerability
Adverse events were reported in 84% of patients, receiving
rituximab, during therapy or within the ﬁrst 30 days
following treatment [4, 35]. However, more than 95% of
these events were described as mild to moderate in severity,
of brief duration, and observed during the ﬁrst infusion.
The most common adverse eﬀects were infusion-related
reactions and lymphopenia. Ten percent of the patients
reported severe fever, chills, infections, or other adverse
eﬀects. Serious adverse eﬀects included severe infusion-
related reactions, tumor lysis syndrome, mucocutaneous
reactions, hypersensitivity reactions, cardiac arrhythmias,
angina, and renal failure [4, 51].
These adverse events were less common during the
subsequent rituximab administrations. One possible hema-
tological adverse event is the reduction in peripheral B-
lymphocyte counts, which can last for up to 6 months with
a recovery period of 9 to 12 months [4, 35]. Nevertheless,
the risk of serious opportunistic infections appears to be
much lower than that reported with conventional therapy
[4]. Interestingly, Bedognetti and coworkers have recently
evaluated the impact of rituximab on the eﬀectiveness of an
antiﬂu vaccine in patients who had previously been treated
with this mAb [52]. Due to the fact that disease status might
aﬀect immune response, only NHL patients without evi-
dence of disease, who had completed rituximab no less than
6monthsbeforetheaccrual,wereselectedforthisevaluation.
The study showed that patients who had previously received
rituximab had a signiﬁcantly lower seroconversion rate in
response to thevaccine.Remarkably,while peripheralCD27-
na¨ ıveBcellswere present, Bedognettietal.found a profound
depletion in CD27+B memory cells, which may well explain
the defective induction of antiﬂu immunity. Thus, concerns
remain that patients who have been treated with the anti-
CD20 mAb may be at risk for infections and that they may
need careful monitoring.
6.Improving RituximabEfﬁcacyand
OvercomingResistance
Despite the expression of CD20 on their lymphoma cells,
some patients exhibit primary resistance and do not respond
well to this targeted antibody therapy. Moreover, an initially
responsive lymphoma can subsequently become resistant to
rituximab (secondary/acquired resistance). Several mecha-
nisms have been reported that have the potential to con-
tributeto reductionsinrituximab eﬃcacy.The identiﬁcation
ofsuchmechanisms hasallowedfortheproposalofstrategies
to overcome these issues, and thus achieve better in vivo
activity. Some of these mechanisms have been reviewed
elsewhere [53]. Here, we will summarize some of the
most recent and promising observations, and the related
suggestions for therapeutic interventions.
(i) Interfering with CD20 Downregulation/Shaving.I n i -
tial in vitro observations suggested that CD20 would
not be downregulated in the presence of anti-CD20
antibodies. Namely, the anti-CD20/CD20 complex
wasfoundtoremainatthecellsurfacelongenoughto
ensure cell killing by speciﬁc mechanisms. However,
these observations may not be reproduced in in vivo
settings. A recent report by Beers et al. showed that
rituximab is able to induce CD20 internalization
in a B-CLL mouse model [54]. Interestingly, these
authorsdemonstratedthatthedegreeofCD20down-
modulation correlates inversely with some types of
NHL’s susceptibility to rituximab. Namely, CLL and
mantle cell lymphoma showed greater downmod-
ulation of CD20 in response to rituximab than
FL and DLBCL did, and were less responsive to
treatment. Previous reports by Beum et al. described
a “shaving reaction” in which mAb-CD20 complexes
were “shaved” oﬀ CLL cells, by phagocytes, as the
malignant cellscirculated[78].Whethertheobserved
reduction in CD20 levels actually reﬂects shaving,
or rather antigen masking by rituximab, remains
unclear [79, 80]. Downregulation of CD20 access,
irrespective of the underling cause, appears to be an
important mechanism aﬀecting rituximab eﬃcacy,as
antigen loss by malignant cells will preventrituximab
activity. New anti-CD20 mAbs (tositumomab-like)
may be able to induce considerably less CD20
down-modulation than rituximab, and thus possibly
be more eﬀective (see below) [54]. It is also of
interest that CD20 expression on lymphoma cells
can be increased with HDAC inhibitors, such as
valproicacidandromidepsin [81].These were shown
to transactivate the CD20 gene through promoter
hyperacetylation and Sp1 recruitment. In line with
these premises, HDAC inhibitors potentiated the
activity of rituximab both in vitro and in vivo in
murine lymphoma models.
(ii) Targeting CD20 Transcript Variants Associated with
Resistance. Henry andcoworkershaverecentlyidenti-
ﬁed an alternative CD20 transcript variant (ΔCD20)
associated with resistance to rituximab [82]. This
novel, alternatively spliced CD20 variant encodes for
a truncated 130 amino acid protein lacking large
partsofthefourtransmembranedomains,suggesting
that ΔCD20 is a nonanchored membrane protein.
ΔCD20 expression was detected in B-cell leukemias,
B-cell lymphomas, and activated B cells, but not in
healthy resting B cells. Finally, the authors went on
to show that ΔCD20 is associated with resistance
to rituximab, although the mechanism whereby this
CD20 splice variant impairs the beneﬁt of rituximab
remains to be determined. The authors suggest that,
given its selective expression in malignant (and
activated) B-cells, ΔCD20 could become a thera-
peutic target, for instance for the development of
antilymphoma vaccines. Whether this approach will
prove eﬀective remains to be assessed.Clinical and Developmental Immunology 7
(iii) Preventing NK Cell-Mediated ADCC Exhaustion.
NK cell-mediated ADCC can be exhausted. Studies
showed that NK cells can engage and kill 3-4 target
cells in 16 hours. Thereafter, cells become exhausted,
possibly due to a reduction in the available levels of
perforin and granzyme B [83]. Indeed, incubation
of NK cells with rituximab-coated target cells leads
to CD16 (FcγRIIIa) downregulation and to upreg-
ulation of CD107a, a marker for degranulation and
exhaustion [84, 85]. Finally, NK cell-mediated target
cell killing was shown to become less eﬃcient in
the presence of high burdens of rituximab-opsonized
lymphomacells[86].Remarkably,IL-2treatmentcan
restore NK cell-mediated ADCC. In line with this
concept, Berdeja and coworkers found that systemic
interleukin-2 and adoptive transfer of lymphokine-
activated killer cells improves antibody-dependent
cellular cytotoxicity in patients with relapsed B-
cell lymphoma treated with rituximab [86]. In this
context, recent studies showed that also complement
c o m p o n e n t s ,s u c ha sC 3 b ,c a ni n h i b i tN K - c e l lm e d i -
ated killing of mAb-opsonized lymphoma cells [55].
Importantly, C3 depletion by cobra venum factor, or
the related drug (HC3-1496), appears to eﬀectively
overcomethismechanism andimprovetheactivityof
rituximab in lymphoma-bearing mice. Thus, overall,
strategies aimed to improve NK cell activity could
help enhance the eﬃcacy of rituximab and should
therefore be further investigated.
(iv) Enhancing CDC. Studies showed that also comple-
ment can be depleted upon rituximab infusion in B-
CLL patients [79]. Kennedy et al. found that fresh
frozen plasma would then restore rituximab eﬃcacy.
More studies on this approach should be performed
in order to conﬁrm its viability. Another approach to
enhance rituximab-induced CDC has recently been
proposedbyWangandcolleagues[87].Theseauthors
observed that many tumors, including lymphomas,
upregulate the expression of CD46, an inhibitory
complement receptor. As a means to overcome
this issue, they identify a recombinant adenovirus
type 35 ﬁber knop protein (Ad35K++) which, when
incubated with lymphoma cells, leads to CD46
downregulation and cooperates with rituximab in
inducing CDC. In xenograft models with human
lymphoma cells, preinjection of Ad35K++ dramat-
ically increased the eﬃcacy of rituximab, suggest-
ing that the Ad35K++-based approach has potential
implications in mAb therapy of NHL. Finally, Sato
and colleagues have recently reported the identiﬁca-
tion of a novel CDC-enhancing variant of rituximab
(113F) [88]. Compared to rituximab, 113F appeared
to mediate highly enhanced CDC against primary
CD20-expressing lymphoma cells in vitro. Moreover,
these authors were able to establishe ahuman tumor-
bearing NOD/Shi-scid-IL-2Rγ(null) mouse model,
in which human complement functions as the CDC
mediator. Using this model, the authors demon-
strated that 113F exerted signiﬁcantly more potent
antitumor eﬀects than rituximab.
(v) Improving Phagocytosis Through CD47 Blockade.
Chao and colleagues have recently shown that
multiple B-cell NHL subtypes, including DLBCL,
FL, and B-CLL, exhibit increased levels of CD47,
a transmembrane protein which activates SIRP1a
in phagocytic cells [89]. This results in initiation
of a signal transduction cascade which leads to
phagocytosis inhibition. These authors demonstrate
that CD47 overexpression correlates with worse
prognosis. Blocking anti-CD47 antibodies promote
phagocytosis of NHL cells and cooperate with rit-
uximab both in vitro and in vivo in murine NHL
xenotransplantmodels.Again,whetherthisapproach
will prove useful in humans remains to be assessed.
(vi) Topical IFN-α Delivery. Finally, Xuan and colleagues
haveproposedanapproachtotargetIFN-αmolecules
to lymphoma sites by constructing a fusion protein
consisting of IFN-α and an anti-CD20 mAb [90].
IFN-αhaspotentimmunostimulatorypropertiesand
antiproliferative eﬀects in some B-cell NHLs, but its
systemic administration is frequently associated to
signiﬁcant toxicity. The CD20-IFN-α fusion proteins
showed eﬃcientanticancer activity against an aggres-
sive rituximab- resistant human CD20+ murine
lymphoma (38C13-huCD20) and a human B-cell
lymphoma (Daudi). Further experimentation with
this administration method is warranted to assess its
applicability in patients.
(vii) Rituximab Mutants with Proapoptotic Activity.I n
order to improve rituximab anticancer activity, Li
and colleagues modulated the binding property of
this mAb by introducing several point mutations
in its complementarity-determining regions [91].
These authors found that the CDC potency of
such CD20 mAbs was independent of the oﬀ-rate.
However, they were able to identify a rituximab
triple mutant (H57DE/H102YK/L93NR) with an
extremely potent apoptosis-inducing activity. This
triple mutant eﬃciently initiated both caspase-
dependent and-independent apoptosis, and exhib-
ited potent in vivo activity even in a rituximab-
resistant lymphoma model. These modiﬁed versions
of rituximab hold promise as new therapeutic agents
f o rB - c e l ll y m p h o m a s ,a l t h o u g ht h e i re ﬃcacy in
patients still has to be assessed.
(viii) Combining Rituximab with Other mAbs. Rituximab
activity in NHL as a single agent is limited, espe-
cially when administered to pretreated patients.
However, combining rituximab with chemotherapy
does achieve signiﬁcantly better outcomes than
chemotherapy alone. In addition, strategies to use
two mAbs have also been proposed. Combinations
such as anti-CD20 plus anti-CD22, anti-CD20 plus8 Clinical and Developmental Immunology
anti-HLA-DR, anti-CD20 plus anti-TRAIL-R1, anti-
CD20 plus anti-CD80 have been evaluated preclin-
ically and/or clinically, showing enhanced antitu-
mor activity both in vitro and in vivo [92–94].
An interesting approach to achieve the beneﬁt of
multiple targeting in NHL consists of the genera-
tion of multivalent antibodies using the so-named
Dock-and-Lock (DNL) method, which enables site-
speciﬁc self-assembly of two modular components
with each other, resulting in a covalent structure with
retained bioactivity [95]. Using this approach, Rossi
and colleagues generated bispeciﬁc anti-CD20/CD22
hexavalent antibodies with promising antilymphoma
activity in vitro and in vivo [96, 97]. Interest-
ingly, in a recent study, these authors were able
to correlate the strong direct cytotoxicity of the
anti-CD20/CD22 hexavalent antibodies, compared
to their bivalent parental antibodies, with their
increased ability to upregulate PTEN, phospho-p38,
and cyclin-dependent kinase inhibitors, such as p21,
p27 and Kip2 [98].
7.Other mAbsforNHL
In addition to the above-mentioned strategies aiming to
improve rituximab activity, numerous research eﬀorts have
led to new mAbs directed against diﬀerent target antigens
and to the development of radioimmunoconjugates. The
most promising newer therapeutics are listed below.
(i) Epratuzumab: a humanized IgG1 anti-CD22 anti-
body. It induces ADCC and CDC in preclinical
studies. Phase I/II studies demonstrated objective
responses in relapsed/refractory FL (24%) [99], and
in DLBCL (15%) [100], without dose-limiting toxic
eﬀects.
(ii) Galiximab: a primatised anti-CD80 (IgG1λ)m A b
with human constant regions and primate (cynomo-
logus macaque) variable regions [101]. CD80 is a
costimulatory molecule involved in regulating T-cell
activation. It is transiently expressed on thesurface of
activated B cells, dendritic cells, and T cells of healthy
individuals [102].Additionally, a variety oflymphoid
malignancies constitutively express CD80, making
this antigen a suitable target [103]. A phase-I/II
study showed that GALIXIMAB is able to enhance
rituximab antitumor activity in previously untreated
NLH patients, with a response reported in 70% of
patients [104].
(iii) Alemtuzumab (Campath): a humanized monoclonal
antibody against CD52 (an antigen expressed by
normalandmalignant B-andT-lymphocytes,mono-
cytes, and NK cells). It is indicated for the treatment
of patients with B-CLL refractory to ﬂudarabine
(ORR of 56%) [105], for advanced-stage mycosis
fungoides/Sezary syndrome [106], and for relapsed
or refractory peripheral T-cell lymphomas [107,
108]. Notably, although clinically eﬀective, this mAb
induces a dramatic decrease in CD4+ and CD8+ T
lymphocytes and thus strongly increases the risk of
infections.
(iv) Apolizumab (Hu1D10): a humanized anti-HLA-DR
antibody that induces CDC, ADCC, and apoptosis.
HLA class II antigens are expressed at the surface
of professional antigen presenting cells, including B
cells. They are involved in antigen presentation and
in promoting cell proliferation. Thus, mAbs against
HLA-DR inhibit B-cell proliferation and induce
apoptosis through activation of the extrinsic apop-
totic pathway. Recently, this type of approach has
shown promising results in B-cell malignances [109].
Single agent therapy APOLIZUMAB in previously
untreated B-CLL patients showed an ORR of 83%
[110]. Moreover, the combination of APOLIZUMAB
and rituximab in relapsed/refractory B-cell lym-
phoma and B-CLL showed an ORR of 42% [111].
(v) Radioimmunotherapy: this type of treatment involves
the administration of an antibody linked to a
radioisotope. This approach permits the targeting
of the radioactive isotopes to cancer tissues and is
especially interesting as it allows for killing neigh-
boring cancer cells that either are inaccessible to
the antibody or express insuﬃcient antigen for the
antibody to bind in adequate quantities. Two anti-
CD20 radioimmunoconjugates are approved for use
in patients with relapsed or refractory follicular or
low-grade lymphoma:
(1) Yttrium-90: labelled ibritumomab tiuxetan
(zevalin),
(2) iodine-131: labelled tositumomab (bexxar).
These therapeutics hold great promise for the treatment
of NHL and their usefulness has recently been conﬁrmed by
several clinical trials [112–122].
About 80% of patients with follicular or low-grade
lymphomas respond to treatment with Zevalin, with 20 to
30% achieving a CR. Interestingly, the duration of response
appears toexceed 3years in about25%ofpatients[123].The
beneﬁt of adding a radioisotope to the antibody was con-
ﬁrmed in a study enrolling patients with indolent NHL that
were refractory to rituximab. In this study, Zevalin showed
a 74% response rate and 15% of CR [115]. Additionally, as
compared to rituximab, Zevalin produces higher response
rates among patients with follicular or low-grade lymphoma
who have not previously received antibody-based treatments
(ORR 80% versus 56%, P = .002; CR 30% versus 16%,
P = .04 [115]). Finally Zevalin also appears to be eﬀective
against some diﬀuse large B-cell lymphomas, and mantle-
cell lymphomas, when used in sequence with chemotherapy
(ORR of 53% versus 19%; OS 22.4, versus 4.6, resp.) [117].
Similar results are obtained with Bexxar. In particular
in patients with NHL refractory to standard chemotherapy,
treatment with Bexxar resulted in CR in 20% of patients
[124]. Additionally, in one study, 95% of patients with
NHL had responses to 131I-labeled tositumomab used asClinical and Developmental Immunology 9
initial treatment, with 75% demonstrating CR [125]. Finally,
the results of a recently completed study (ClinicalTrials.gov
number, NCT00006721), comparing CHOP followed by
131I-labeled tositumomab to rituximab plus CHOP for the
initial treatment of FL, is predicted to redeﬁne standard
therapy for this disorder.
Importantly, there are other radiolabeled immunother-
apeutics for NHL that are currently under evaluation [112,
114, 126–130]. These include
(a) LL2 anti-CD22, conjugated to either 131Io r90Y; Lym-
I;
(b) anti-HLA-DR, conjugated to 90Yo r67Cu;
(c) rituximab, conjugated to 211At, 186Re, or 227Th;
(d) anti-CD19 mAb conjugated to 90Y.
8.Conclusionsand Perspectives
Combining rituximab with chemotherapy has proven to be
an eﬀectivetreatment for bothindolent and aggressive forms
o fN H L .T h es a m et y p eo ft r e a t m e n tc a nb eu s e di np a t i e n t s
with B-CLL, although its eﬃcacy in this disorder appears
to be lower. In addition, it has also been demonstrated that
usingrituximabaloneasamaintenancetherapyimprovesthe
prognosis andextends disease-free survival inFL.Althougha
standard scheme for rituximab maintenance therapy has not
been established yet, it is currently under investigation and
the ongoing studies will establish the most eﬀective regimen.
For patients in which treatment with rituximab has not
given the expected results, autologous stem cell transplan-
tations have shown promise. It has been demonstrated that
using a cycle of rituximab in association with stem cell
transplantations and after it as maintenance therapy, yields
better results than transplant alone.
Radiolabeled antibodies may be eﬀective in rituximab-
resistant and chemotherapy-resistant disease, but their clin-
ical use is still limited when compared to that of unla-
beled mAbs. Recent data suggest that sequential radioim-
munotherapy after chemotherapy may have signiﬁcant clin-
ical value. Additionally, novel monoclonal antibodies are
under development. If these will prove to be more eﬀective
than rituximab will have to be assessed by randomized
comparative trials.
Overall, the results obtained with antibody-based thera-
peuticsin NHL are clearly highly promising. They herald the
advent of therapeutic strategies based ontargeted agents that
will likely be more eﬀective and, at the same time, less toxic
than traditional chemotherapy-based treatments.
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